Highlights of This Issue 2341

CANCER GENES AND NETWORKS

2343 Adaptive Protein Translation by the Integrated Stress Response Maintains the Proliferative and Migratory Capacity of Lung Adenocarcinoma Cells
Alexandra E. Albert, Sally J. Adua, Wesley L. Cai, Anna Arnal-Estapé, Gary W. Cline, Zongzhi Liu, Minghui Zhao, Paul D. Cao, Malaiyalam Mariappan, and Don X. Nguyen

2356 Distinct Roles for BET Family Members in Estrogen Receptor α Enhancer Function and Gene Regulation in Breast Cancer Cells
Shino Murakami, Rui Li, Anusha Nagari, Minho Chae, Cristel V. Camacho, and W. Lee Kraus

2369 SIX1 Regulates Aberrant Endometrial Epithelial Cell Differentiation and Cancer Latency Following Developmental Estrogenic Chemical Exposure
Alisa A. Suen, Wendy N. Jefferson, Charles E. Wood, and Carmen J. Williams

2383 The Notch Pathway Promotes Osteosarcoma Progression through Activation of Ephin Reverse Signaling
Ling Yu, Kezhou Xia, Tian Gao, Jingteng Chen, Zhengwei Zhang, Xiangran Sun, Bruno M. Simões, Rachel Eyre, Zhengfu Fan, Weichun Guo, and Robert B. Clarke

2395 Phosphoinositide 3-Kinase Signaling Can Modulate MHC Class I and II Expression

CANCER "-OMICS"

2410 Comparative Genomics Reveals Shared Mutational Landscape in Canine Hemangiosarcoma and Human Angiosarcoma

2422 Outcome-Related Differences in Gene Expression Profiles of High-Grade Serous Ovarian Cancers Following Neoadjuvant Chemotherapy
David Octeau, Roy Kessous, Kathleen Klein, Liron Kogan, Manuella Pelmus, Alex Ferencyz, Celia M.T. Greenwood, Leon C. Van Kempen, Shannon Salvador, Susie Lau, Patricia N. Tonin, Amber Yasmine, and Walter H. Gotlieb

2432 Genetic and Epigenetic Characterization of Growth Hormone–Secreting Pituitary Tumors
Niko Vallimäki, Camilla Schalin-Jantti, Atte Karppinen, Anders Paetau, Leena Kivilpelo, Lauri A. Aaltonen, and Auli Karhu

CELL FATE DECISIONS

2444 The Zinc-Finger AN1-Type Domain 2a Gene Acts as a Regulator of Cell Survival in Human Melanoma: Role of E3-Ligase cIAP2
Sofia Pizzato Scomazzon, Anna Riccio, Silvia Santopolo, Giulia Lanzilli, Marta Coccia, Antonio Rossi, and M. Gabriella Santoro

2457 Therapeutic Implications of p53 Status on Cancer Cell Fate Following Exposure to Ionizing Radiation and the DNA-PK Inhibitor M3814
Qing Sun, Yige Guo, Xiaohong Liu, Frank Czauderna, Michael J. Carr, Frank T. Zenke, Andree Blaukat, and Lyubomir T. Vassilev
Sophoridine Inhibits Human Colorectal Cancer Progression via Targeting MAPKAPK2
Rui Wang, Hongwei Liu, Yingying Shao, Kailong Wang, Shuangshuang Yin, Yuling Qiu, Honghua Wu, Rui Wang, Xiuhua Gao, and Haiyang Yu

Functional Loss of ATRX and TERC Activates Alternative Lengthening of Telomeres (ALT) in LAPC4 Prostate Cancer Cells
Mindy K. Graham, Jiyoung Kim, Joseph Da, Jacqueline A. Brosnan-Cashman, Anthony Rizzo, Javier A. Baena Del Valle, Lionel Chia, Michael Rubenstein, Christine Davis, Qizhi Zheng, Leslie Cope, Michael Considine, Michael C. Haffner, Angelo M. De Marzo, Alan K. Meeker, and Christopher M. Heaphy

A Unique Morphological Phenotype in Chemoresistant Triple-Negative Breast Cancer Reveals Metabolic Reprogramming and PLIN4 Expression as a Molecular Vulnerability

Prostate Tumor Cell–Derived IL1β Induces an Inflammatory Phenotype in Bone Marrow Adipocytes and Reduces Sensitivity to Docetaxel via Lipolysis-Dependent Mechanisms
Mackenzie K. Herroon, Jonathan D. Diedrich, Erandi Rajagunanthara, Carly Martin, Krishna R. Maddipati, Seonho Kim, Elisabeth I. Heath, James Granneman, and Izabela Podgorski

Functional Analysis of Aberrantly Spliced Caspase8 Variants in Adult T-Cell Leukemia Cells
Kazumi Nakano, Masako Iwanaga, Atsuo Usunomiya, Koichi Uchimura, and Toshiki Watanabe

Serum CD95L Level Correlates with Tumor Immune Infiltration and Is a Positive Prognostic Marker for Advanced High-Grade Serous Ovarian Cancer
Thibault De La Motte Rouge, Julien Corné, Aurélie Cauchois, Marie Le Boulch, Clotilde Poupon, Sébastien Henno, Nathalie Rioux-Leclercq, Esther Le Pabic, Bruno Laviolle, Véronique Catros, Jean Levêque, Alain Fauteur, Matthieu Le Gallo, Patrick Legembre, and Vincent Lavoué

For more information please visit www.aacrjournals.org
ABOUT THE COVER

Clinical management of triple-negative breast cancer (TNBC) relies heavily on the use of cytotoxic chemotherapy but acquired resistance to these interventions is common. The cover depicts array comparative genomic hybridization analysis of TNBC cells which had been cultured in the presence of the topoisomerase-2 inhibitor doxorubicin (DOXO). DOXO-resistant cells from multiple clones acquired recurrent chromosomal copy number variations (red dots: copy number gain; blue dots: copy number loss) which persisted after the withdrawal of DOXO and were associated with altered cellular morphology and metabolism. The authors also found that these phenotypic and molecular characteristics were associated with chemotherapy-resistant TNBC in clinical samples, thus nominating new targets that may benefit patients who reach this stage of disease. See the Highlight on page 2341 and the article on page 2492 for more information.
Molecular Cancer Research

17 (12)


Updated version
Access the most recent version of this article at:
http://mcr.aacrjournals.org/content/17/12

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://mcr.aacrjournals.org/content/17/12.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.